text:
Groups Petition
EPA to Ban Hazardous Wood Preservatives
Citing government inaction to protect the nation's children from exposure to widely used and highly toxic wood preservatives, leading environmental and public health groups today petitioned EPA to immediately stop the continued use of chromated copper arsenate (CCA) and pentachlorophenol (penta). The groups say that EPA has sufficient data on wood preservatives' health and environmental risks and economically viable alternatives to initiate cancellation and suspension proceedings, rather than conduct further reviews.
"Comprehensive EPA action to protect children and the public from wood preservatives is long overdue," said Jay Feldman, executive director of Beyond Pesticides, a Washington-based public advocacy organization and lead petitioner. In the petition, the groups cite high cancer risks from exposure to wood surfaces of playground equipment treated with CCA, which contains high levels of arsenic as a major component, and soil that has become contaminated. Earlier this year, the Governor of Florida, Jeb Bush, closed contaminated parks and took steps to curtail future use of arsenic treated wood.
There are a number of principal users of chemically treated wood products, including utility companies (treated wood poles), construction companies (treated lumber) and the railroad owners (treated railroad ties). Wood treated with CCA is widely available through retail markets, such as Home Depot and Lowes Home Improvement.
CCA and penta are linked to a large number of health problems including cancer, birth defects, kidney and liver damage, disruption of the endocrine system and death. In fact, two of the components of CCA, arsenic and chromium (VI), are classified as known human carcinogens. Penta, classified as a probable carcinogen and a known endocrine disruptor in its own right, is contaminated with dioxins. The National Institutes of Health recently classified dioxin as a known human carcinogen.
EPA has calculated that children exposed to soil contaminated with penta leaching out of utility poles face a risk of cancer that is 220 times higher than the agencys acceptable level. Research faculty at the University of Miami and the University of Florida have found elevated levels of arsenic in the soil around wooden decks and boardwalks in Miami, Gainesville and Tallahassee, Florida. This research was conducted under the sponsorship/funding of the Florida Center for Solid and Hazardous Waste Management. Researchers from the Department of Health Services of the State of California found that children could get enough arsenic on their hands from touching treated wood playgrounds and decks to pose a significant health risk. Workers who paint penta on to poles in the field face a 100 percent risk of cancer. The practice of allowing the disposal of treated wood in unlined dumps or its recycling in mulch is exacerbating contamination and risk factors, according to the petition.
Groups joining the petition include, Beyond Pesticides/National Coalition Against the Misuse of Pesticides, Agricultural Resources Center, Center of Health, Environment and Justice, Clean Water Action, Greenpeace USA, Healthy Building Network, Learning Disabilities Association of America, Northwest Coalition for Alternatives to Pesticides, Vermont PIRG, and Washington Toxics Coalition.
Both the petition regarding CCA, and the petition concerning penta are available to view on our website.


text:
Rob Allen has posted this look at using hooks inside of action helpers (a follow-up from his previous article on action helpers):
Hooks are a feature of action helpers that allow you to automatically run code at certain points in the dispatch cycle. Specially, there are two hook functions available for action helpers: preDispatch and postDispatch. These allow you to ensure that some functionality is always run for each request.
He creates a simple action helper that grabs a random quote from an array and drops it into a property of the helper. By defining a preDispatch method inside of the helper, the HelperBroker knows to pull the method in an execute it immediate before the rest of the actions are executed. A calls to addHelper with the hooks defined is all it takes to glue it together with the execution.

subset: commoncrawl


text: His Royal Peetness is huzzahing like a madman at Chrysler's decision to do in the Imperial, calling it "the wrong car, at the wrong time, from the wrong car company" and hoping that the decision to cancel the ill-proportioned behemoth may be the sign of common sense beginning to prevail in the hallways of Auburn Hills. Needless to say, the situtation with CerbChryCo is touch-and-go right now, but here's to hoping that the 2008 round of show vehicles have a bit more in the way of er, zazz. Actually, could they do a rethought ZAZ? Murilee, for one, would blow his spleen with glee. [Autoextremist]


text:
Today is my last day at my current job. A job I've been with for nearly four years. My first job out of college. My first taste of the real world.
While I am happy that I am embarking on a new journey on Monday, I can't help but feel a little sad that I am leaving a job and coworkers who have been a huge part of the last four years.
I am so thrilled that I got to work here while I did, and I am very thankful for the opportunities that this job has provided me. But, I am ready to take a leap of faith, and pave myself new path in a different direction. I am going to enjoy the journey, and I look forward to see where this decision will eventually take me.
And thank you, too, to all of you who have shown your support during this time. The decision-making process has not been an easy one, but sticking with my guns and following through with this has been so much easier knowing I have my friends and family backing me up.
You all are the best. The cat's meow. The bee's knees.
So how about we focus now on something sweet, tasty, and delicious?
There are quite a few people who have yet heard of the wonderful dessert called the Kentucky Derby Pie. I liken it would be similar to the love-child of a pecan pie and a chocolate chip cookie (though some people think the pie should have walnuts, I grew up with pecans, so I'm sticking with my guns here).
When I made desserts for the National Food Blogger's Bake sale, I wanted to make things that traveled easily, and tasted delicious. The fact that these mini-pies were absolutely cheek-pinchingly adorable was just an added bonus.
The only thing missing from the mini pies that I wish I could have found a way to package was the bourbon whipped cream that my family makes to serve the pie with. Essentially you whip up one cup of heaving whipping cream with one tablespoon of powdered sugar and 2 teaspoons (or one tablespoon if you're feeling rather daring!) of bourbon.
Nothing like a little bit of bourbon to cure what ails ya.


text:
Carroll Beach, board chairman of Elevations Credit Union, has been presented the inaugural Distinguished Service Award by the Mountain West Credit Union Foundation.
The award recognizes individuals who are dedicated to "unwavering" service to the credit union industry, according to the foundation.
Beach has spent his entire professional career in the credit union industry, including having served as president of the Credit Union Legislative Action Committee, the Colorado Credit Union Foundation, Credit Union Family Insurance Services, and Credit Union Advantage Automotive. He has also managed the state trade association and many other credit union-related organizations and institutions.


text:
Women's Vintage Brands
Shop true vintage brands & vintage from around the world. From denim standards Levi's, Wrangler, G-Star, Lee, and full of authentic pieces from heritage brands such as Burberry, Harris Tweed. You can also browse vintage items from Lacoste, Diesel, Barbour, Adidas, Tommy Hilfiger and more. Keep an eye on our New In section as we have great new products coming every day.


text:
Before I leave my house for a trip, I have to use up all of the food in my refrigerator. If I don't, I'll be wracked with guilt, or worse. Like the time I had a full-blown panic attack somewhere in the blue skies over Arizona because I had realized that I had forgotten to use up the last half of a head of radicchio.
So prior to leaving for New Orleans recently, I made sure to use up all of the produce, meat and dairy in my fridge well before I even boarded the plane in San Diego. That's how I ended up making this Escarole and Parmesan Risotto.
The night before we left, I opened my crisper drawer to find a lonely head of escarole. Since I didn't have any cannelini beans, I knew escarole and beans was out, so I did what any good Italian would do and carbed up with risotto.
Whether you love making risotto or become short of breath at the mere thought of all that stirring, you might like to check out my NPR article, "Taking The Risk Out Of Risotto." I show you how to make perfect risotto every time without constantly stirring. I also share recipes for Autumn Risotto with Apples, Pancetta, and Sage, Risotto with Broccoli Rabe and Sun-Dried Tomatoes and Pumpkin Pie Risotto with Candied Pecans.
Oh, and you might like to know that my trip to New Orleans was turbulence-free.
Escarole and Parmesan Risotto
Makes 4 servings
Printable recipe.
3 1/2 cups regular or low sodium vegetable broth
2 teaspoons butter, plus 1 tablespoon
2 teaspoons olive oil, plus extra for drizzling
1 shallot, diced
1 cup arborio rice
1/2 cup dry white wine
4-5 packed cups escarole, thinly sliced, divided
The zest and juice of 1/2 of a medium lemon
3/4 cup grated Parmesan cheese, plus extra for garnish
Salt and freshly ground black pepper, to taste
1. In a large saucepan over medium heat, bring broth to a simmer.
2. For the risotto, heat 2 teaspoons butter and 2 teaspoons olive oil in a wide, shallow, heavy-bottomed saucepan over medium heat. Add diced shallot and saute 3 minutes, or until tender and translucent. Add the rice and toast for 1 to 2 minutes, or until slightly translucent. Add the wine and stir until it has evaporated. Add 3 cups escarole and a couple of pinches of salt and freshly ground black pepper. Stir well. Cook the risotto at a slow simmer, adding heated broth a half-cup at a time. Stir occasionally, making sure the risotto absorbs the liquid before adding more. Use slightly more or less broth as needed. Continue cooking in this manner for 18 to 20 minutes. Near the end of the cooking process, stir in the remaining escarole and lemon zest and juice; season with more salt and black pepper. Taste the risotto — it should be creamy and thick. It's best al dente, which means it should be fully cooked, yet still retain some firmness when you chew it.
3. When the risotto is cooked, turn off heat and stir in 1 tablespoon of butter and 3/4 cup grated Parmesan cheese. Season to taste with salt and freshly ground black pepper. Serve risotto on warm plates and sprinkle with extra grated cheese and, if desired, a drizzle of extra virgin olive oil. Serve immediately.
Here are more delicious risotto recipes you might enjoy:
Lobster Risotto recipe from Food Blogga
Winter Risotto recipe from Proud Italian Cook
Risotto with Swiss Chard recipe from The Way the Cookie Crumbles
Butternut Squash Risotto with Seared Scallops recipe from gourmet traveller
Sweet Potato and Spinach Risotto recipe from Two Peas and Their Pod


text:
704 members418 Comments 193 Likes
4133 members1749 Comments 273 Likes
876 members18384 Comments 89 Likes
Started this discussion. Last reply by Tammy S Jul 30, 2012. 1 Reply 0 Likes
I'm still fairly new here, but wanted to share the project I'm working on at the moment.Background: I'm an atheist in the UK and a filmmaker. I have lots of atheist friends in the US who will often…Continue
Tags: documentary
Started this discussion. Last reply by Sylvia Broeckx Jun 14, 2012. 7 Replies 0 Likes
Please allow me to introduce myself. I'm Sylvia, a 34 year old filmmaker currently residing in Sheffield UK, but originally from Belgium. And I'm an atheist. Like most people in Belgium I was raised…Continue
Sylvia Broeckx has not received any gifts yet
Ooh, looks cool and useful, perhaps as a movie for younger atheists to show their ignorant, religious family members.
Your statement about the perspective of atheism in the USA reminds me of an episode of Top Gear that I saw a few years ago. The guys were on a road trip from Florida to New Orleans, Louisiana. While passing through either Alabama or Mississippi, the hosts (who were each driving their own car) were given a challenge by the show producers to paint messages on the sides of the others' cars, in an attempt to get the other hosts assaulted.
There were messages such as NASCAR sucks, Hillary Clinton for President (before she actually ran for president), and Man Love is Okay. They actually got assaulted and there was only sketchy film coverage, as the film crew ran for their lives, when they got jumped and were chased after by a bunch of yahoos in pickup trucks.
I think most Europeans seriously don't grasp the fact that ... all of the horrifying stereotypes you see on American TV programs and movies, mocking southerners ...
The reason those stereotypes exist is that it's the honest truth about a huge portion of the population, in several of the southeastern states. It's not hyperbole. Most Europeans haven't come face-to-face with that level of ignorance, stupidity, and hatred in such overwhelming numbers, and they can't make themselves truly believe it. The Top Gear guys now clearly believe, though.
Cool. What sort of films are you working on?
Welcome Sylvia! I hope you will enjoy it here!
Welcome aboard! =) Hope you're doing well today...
Welcome, Sylvia! Glad you could join us. :D
Please consider joining a group to meet people and talk about anything that's on your mind, Hang With Friends. After you've searched for topics of interest in "Groups" above and in the "Forums", don't forget to look at recent activity which hides along the right margin of the page all the way at the bottom.
Hi Sylvia
Welcome to this world of rationality, truth and peace, where common sense and science lead to freethinking wisdom --- as you know as a life long atheist film maker and freethinker.
We invite you to make good friends by joining the busy group "ORIGINS: Universe, Astronomy, Life, Earth, Humans, Religion, Gods, Atheism, Evolution, Darwin..." with 700 discussion topics and 3500 members. http://www.atheistnexus.org/group/originsuniverselifehumankindanddarwin Terry
© 2020 Atheist Nexus. All rights reserved. Admin: The Nexus Group. Powered by


text:
International Students at Pacific
A complete Application for Admission for International Students includes:
- Application for Admission
- Required Personal Statement (Personal Essay on the Common Application)
- Official Records of Study
- Demonstration of Proficiency in English
- Recommendation
- Certification of Finances
- Clear copy of Passport Photo Page
An explanation of each element of the complete application follows:
Application for Admission
The Application for Admission ("Pacific Scholar Application" or "Online Application") must be completed in full, signed by the applicant and submitted to the Office of Admission.
You can mail it to the Office of Admission or submit the application electronically.
Important — Please make sure that the family name (last name) and given name (first name) on your application for admission exactly match the names on your passport. This will ease processing of your immigration documents if you are admitted and choose to enroll.
Required Personal Statement (Personal Essay on the Common Application)
Submit a brief personal statement (250 to 500 words) - as a way to get to know you as a person and more than a collection of classes and test scores. Relax - there are no wrong answers. But we do ask you to consider grammar, spelling and the content of what you wish to express.
The topic is up to you, but if you need some help getting started, here is an idea:
"Describe your professional and educational goals in conjunction with your selected major choice."
"Describe your professional and educational goals in conjunction with your selected major choice"
Official Records of Study
You are required to arrange for the Office of Admission to receive official or certified copies of your academic records for all secondary and post-secondary (including college, university, institute or professional school) study. Official or certified copies of results of public or external examinations you have taken are also required. These should be sent, whenever possible, by the examining authority itself.
Records should list the subjects studied and the grade or mark received. Records should include copies of degrees, diplomas or certificates received. The University expects official copies of the original document in the official language of the educational system. If that language is not English, an official translation should be attached.
You may submit officially certified or attested photocopies of original records. If your application is approved, you will be expected to present the originals to the Admission Office for inspection prior to registration.
Additional Requirements for Undergraduate Applicants Seeking International Transfer Credit
Students who attended universities outside of the United States and wish to attend University of the Pacific must go through a four step process, including a required transcript evaluation and official course descriptions. You can find details about the process at our International Coursework page.
Scholastics Assessment Test (SAT) / ACT
All freshman applicants to the Pre-Pharmacy Advantage, Accelerated Pre-Dentistry, Biological Sciences, Chemistry, or Dental Hygiene programs must submit either Scholastic Assessment Test (SAT Reasoning Test) or the ACT (Writing section included) scores.
Students applying for the following majors should also take the SAT Subject Test in Chemistry:
Biological Sciences, Biochemistry, Bioengineering, Chemistry, Chemistry-Biology, Civil Engineering, Dental Hygiene, Dental/Pre-Dental, Electrical Engineering, Engineering Management, Engineering Physics, Mechanical Engineering, Physics, Pre-Pharmacy
University of the Pacific's SAT code is 4065.
University of the Pacific's ACT code is 0240.
To receive further information in connection with this requirement, please contact the Office of Admission.
English Language Proficiency
If your native language is not English, you must submit official results of one of the following in order to receive consideration for admission:
|Test Type
|All Majors
|Internet-based TOEFL
|Paper-based TOEFL
|IELTS score of
All international students are required to take placement tests to demonstrate writing, math, and other proficiencies during New Student Orientation Week.
Information about TOEFL can be located online at http://www.ets.org/toefl; information about IELTS can be located at http://www.ielts.org. The University of the Pacific's TOEFL Code is 4065.
All international applicants are required to take the TOEFL or IELTS unless they meet one of the following waiver requirements:
- SAT Evidence-Based Reading and Writing (Verbal) of 570 (new SAT) or 510 (old SAT). University of the Pacific's SAT code is 4065.
- ACT Composite score of 22 or higher. University of the Pacific's ACT code is 0240.
- One academic year (two semesters, or four quarters) of any two of the following courses at a university in the United States, both with a grade of B or higher: English Composition, Critical Thinking, Communications. Citizens of the following countries: Australia, Canada, New Zealand, United Kingdom and South Africa. If you are a citizen of one of these countries, you must take the SAT or ACT instead of an English language proficiency test. International transfer students with more than 30 units of college work do not need to take the SAT or ACT.
- All high school instruction in the U.S. and in English*
- "A" level English scores of B or higher*
- AP English score of 4 or higher*
- IB English score of 5 or higher*
*You must take the SAT or ACT instead of an English language proficiency test if you meet these waiver requirements.
The recommendation form must be completed by a counselor, principal, director or other responsible official of the institution in which you are currently enrolled or which you last attended. If you have been out of school for more than two years and have been employed full-time, you may ask your employer to complete the form. More information on how to submit a recommendation can be found by visiting: http://www.pacific.edu/recommendation
Certification of Finances
Total cost of attending University of the Pacific can be found here. University costs rise approximately 6% each year.
Download the Financial Responsibility Form (PDF) for the 2019-2020 Academic Year.
All international students requiring an F1 visa must provide the University with a recent financial guarantee or recommendation in the form of a letter or account statement from a financial institution, which demonstrates funds equivalent to one year of study at Pacific. If your study will be sponsored by a government agency, foreign embassy or a private individual (other than your parent or guardian), the sponsor must submit a letter to the University indicating they will pay for your studies. The sponsor must also submit an account statement showing the specific dollar amount per year available to you and the duration of its availability.
The University may require further certification of finances or advanced payment of tuition and fees from students whose funds originate in countries where severe currency restrictions exist. If you will be accompanied in the U.S., allow $3,000-3,500 per year for each dependent. The University cannot send you forms for your student visa until complete financial certification has been obtained.
Information on Estimated Cost of Attendance for International Students at Pacific
The University of the Pacific requires a clear copy of the photo page of the student's passport. Both the photo and the text must be legible.
Financial Assistance
University of the Pacific offers a number of $15,000 International Student Merit Scholarships to international students applying as freshman or transfer students. For more information, please visit the International Students Scholarship page. To be considered for a merit-based scholarship, you must simply submit an application for admission and all supporting items. You will be notified of an award if you admitted and qualify for an award. Athletic scholarships are also available to international students.
International freshman students are welcome to apply for University of the Pacific's Powell Scholarship for $42,000 and extra funding for education abroad and research opportunities. For more information, please visit the Powell Scholarship page.
Additional Requirements for Certain Programs
Applicants to the Conservatory of Music
Those interested in applying to the Conservatory of music must present evidence of musical talent and achievement by performing an audition. Those planning to major in composition must also submit an original composition. Instructions are available from the Office of the Dean of the Conservatory of Music or at http://www.pacific.edu/audition
Pacific Legal Scholars Candidates
Strong candidates applying for the Pacific Legal Scholars Program will be expected to complete an interview either on campus or by phone after the application is complete. The Director of the program will contact prospective students for the interview during the spring semester. Additional information on the Pacific Legal Scholars Program can be found here.
Pacific Humanities Scholars Candidates
Strong candidates applying for the Pacific Humanities Scholars Program will need to complete an interview with the Program Committee. Interviews ideally should take place on campus, but can also be completed via phone or Skype. Qualified candidates applying for Humanities-related majors may also be contacted by the Program Committee with an invitation to interview. The Program Administrative Assistant will contact prospective candidates to coordinate the interviews as applications are complete. Additional information on the Pacific Humanities Scholars Program can be found here.
Interviews and Auditions
Additional Information about Interviews and Auditions
University of the Pacific is a residential university. Most of its students live on the University campus in residence halls operated by the University's Housing Office. Most residence halls are coeducational (for both men and women), but the University also has facilities exclusively for women. The University requires all first- and second-year students to live in University housing. Exceptions may be given to those living with their parent(s) or to those who request exception due to medical or religious reasons. The University has limited facilities for married students.
Application Decision and Notification
The Office of Admission will review your application as soon as it and all supporting documents are received and will notify you of its decision as promptly as possible.
Reply Date and Confirming Deposit
If you are offered admission to the University, the Office of Admission will specify in the approval letter a "reply date." This is the date by which you must reply to the admission offer. If you decide to accept the University's offer of admission you must make a U.S. $400 deposit by the reply date. The deposit will be credited toward your tuition for your first term of study. If your study at University of the Pacific will be sponsored by a foreign embassy or government, you must make certain that the deposit is made for you, or you must make the deposit yourself.
Medical Questionnaire
On approval of the application for any regular term, a medical questionnaire will be sent to you for completion and return. This report is required of all students registering for more than 6 semester units and must be filed prior to registration.
Honor Code
Established in 1958, the Honor Code is intended to maintain and preserve the high standards of personal character and integrity vital in academic pursuits. The success of the honor code is made possible only with the acceptance and cooperation of every student. We fully expect that every University student will join with us in maintaining the principle and the tradition of the code in all aspects of college life.
Applicants for admission to the University are asked to recognize the responsibilities of the code and to accept its principles. Your signature on the application form or electronic signature from the online application indicates that you agree to uphold the principles of the code. For more information please see the Tiger Lore and the Pacific Guide.


text:
If you live in the Hudson, Quebec area and you've built or renovated a house in the past three generations, chances are that you or your family have trusted the Crombie family to help. When contractors, DIYers and consumers need lumber, building materials and hardware, it's Hudson's they count on for selection, service and experience. You get expert advice at Hudson Renovation, along with great quality and pricing.
Browse our product catalogue and ideas gallery. We've included links to the websites of some of our suppliers to help you find what's right for your needs - roofing, windows, paint, flooring, lumber and more. If you're ready to get started on a project right now, request a quote. If you don't see what you're looking for, let us know and we'll get it for you.
Our Price: $42.99 EA
Product Code: 7563380
Show the "Electrical" category
All trademarks, service marks, logos, graphics, product names and company names are the property of their respective owners.


text:
Refine results
Keyword search
- Outdoors and exterior only (1)
- Accessible by public transport (22)
- Bicycle rack (10)
- Bus parking (23)
- Car parking (56)
- Children's quiz available (25)
- Disabled toilets (16)
- Display on history (23)
- No dogs allowed except assistance dogs (10)
- Guided tours – ask on site for details (3)
- May close for lunch in winter, please call in advance (5)
- May close for lunch, please call in advance (15)
- Mobility scooters available (2)
- Picnic area (18)
- Restaurant/café (6)
- Self service tea/coffee (5)
- Shop (29)
- Strong footwear recommended (67)
- Toilets (25)
- Visitor centre (11)
- Water bottle refill (21)
Search results
The search has returned 115 placesRefine results
Antonine Wall: Bar Hill Fort
Observe the spectacular views from the highest fort on the Antonine Wall.
Antonine Wall: Bearsden Bath House
Get an insight into the everyday lives of Roman soldiers stationed on the Antonine Wall.
Antonine Wall: Croy Hill
See where Romans cut a ditch through solid rock at this Antonine Wall fort.
Antonine Wall: Dullatur
Stroll along the frontier of the Roman Empire at the site of two Antonine Wall camps.
Antonine Wall: Westerwood to Castlecary
Roam a section of the north-west frontier of the Roman Empire.
Ardclach Bell Tower
Discover a true architectural oddity in this little fortified bell tower, built on a hilltop by a noted Covenanter.
Auchagallon Cairn
Roam an ancient burial place overlooking a bay on one of Scotland's most beautiful islands.
Auchindoun Castle
Trek up to the lonely ruin and surrounding earthworks of a 1400s stronghold.
Balvenie Castle
Face a mighty, curtain-walled fortress, built in the 1200s as the seat of the powerful earls of Buchan.
Barochan Cross
Admire the stonework of a rare surviving cross from an early medieval kingdom.
Beauly Priory
Explore the ruined church of a little-known order of monks in a wooded, riverside location.
Biggar Gasworks Museum
Enter what was one of the first small-town gasworks to open in Scotland – and among the last to close.


text:
Equalizer 2, The R
play trailer
Play Trailer
DetailsAction/Adventure , Suspense/Thriller
Play Trailer
Denzel Washington returns to one of his signature roles in the first sequel of his career. Robert McCall serves an unflinching justice for the exploited and oppressed - but how far will he go when that is someone he loves?
DetailsAction/Adventure , Suspense/Thriller
2 hr. 0 min.
Opened July 20th, 2018
Rated R for brutal violence throughout, language, and some drug contentCastDenzel Washington, Pedro Pascal, Ashton Sanders, Bill Pullman, Melissa LeoDirectorAntoine FuquaWriterRichard Lindheim
Richard Wenk


text:
Hunter College – 63, Farmingdale State – 60
Farmingdale, N.Y. – The visiting Hunter College women's basketball team (12-13) took a non-conference victory over Farmingdale State tonight, 63-60. The Hawks trailed late in the second half, but were able to complete the comeback in the final seconds for the victory. The Rams fall to 13-8 with the loss.
The Rams trailed by seven halfway through the first half before a 13-4 run tied the game at 17-17 with 5:53 left to play. Hunter led 28-23 at the break, behind 13 points and six rebounds from sophomore forward Kristen Markoe (Staten Island, N.Y.).
In the second, Farmingdale stole back the lead early, 31-30, with 17:18 remaining and would hold a convincing lead over the next 10 minutes. With 4:34 remaining and the Rams ahead 58-47, the Hawks went on an 11-0 run to tie the game at 58-58 with 1:13 to go.
Freshman guard Shatira Hamlet (Rosedale, N.Y.) made a layup at 0:34 to give Hunter the 60-58 edge. On the Rams next possession, with one second on the shot clock, junior guard Baytania Newman (Brooklyn, N.Y.) took an inbounds pass and tied the game at 60-60 with 17 seconds left.
Hamlet streaked down the court on a fast break and once again put the Hawks ahead, 62-60, and was fouled. She completed the 3-point play for a 63-60 score with 10 seconds left. Farmingdale took two 3-pointers but none would fall as the Hawks came away with the win.
Hamlet finished with a game-high 19 points and four assists. Markoe had the games only double-double of 17 points and 11 rebounds, along with four assists and four steals. Junior guard Erika DeJesus (New York, N.Y.) totaled 10 points and seven rebounds.
For Farmingdale State, junior guard Jeanette Zubizarreta (Bay Shore, N.Y.) scored 15 points, while Newman finished with 14 points and senior forward Dominique Cunningham (Amityville, N.Y.) had 12 points and a team-high nine rebounds.
The Rams will now host the College of Staten Island on Thursday, February 16th at 5:00 p.m. This will mark Senior Night for the Rams, and the Play4Kay game, our annual breast cancer fundraiser. The Rams are asking fans to wear pink in an effort to raise awareness for a cure for cancer. A $2 donation will be collected at the door, if you wear pink it will be $1. Raffles will be available, a halftime contest and a 50/50 raffle.
See you there!


text:
I don't think I'm cheap, but what do I know? My view is that I love this inanimate object not – at least not primarily – for moneysaving reasons, but because it's existence fills me with wonder, excitement, hopefulness and joy. It's almost like magic, though come to think of it, everything I don't understand feels, to some degree, like magic, including how, though billions of phone calls are being bounced off satellites at the same time, you never get somebody else's call by mistake. The light bulb also knocks me out. A heat bulb I could understand. You plug something in, and it gets hot, like a waffle iron. But where does the light come from? Don't tell me. I would miss going "Look at that!" every time it goes on.
Okay, so there's this store – it's still around – in a "walking street" mall near my house called the Z Gallery. This was the store where I bought this wonderful thing I'm about to talk about, although since that time, the place has completely altered its inventory, and not for the better. There is now nothing in there I would want to purchase. No "wonderment" items whatsoever. Mostly, it's really ugly lamps. Did you ever wonder who buys the stuff that you think is hideous? I do, all the time. Just once, I'd like to walk up to the checkout counter as they're paying for their coveted monstrosity and go,
Anyway, about twenty-five years ago – don't hold me to that, old people are notoriously inaccurate about the dating of past events – I say something happened ten years ago and it was twenty years ago; I believe as you get older, the years somehow become shorter – anyway, I walked into the Z Gallery, at the time when they sold less unattractive furniture accessories and more chazzerai (assorted knickknacks) – and I discovered and felt immediately compelled to buy, at a price of twenty-two dollars, a smallish (maybe six by nine inch), flat, molded black plastic, what was promoted as:
A solar calculator.
This description seemed mislabeled to me, because, despite its being "solar", I was never required to stand in the sun to use it. I do not have to calculate outdoors at all. I can calculate in my office. And I don't even have to stand by the window. I can use it when the blinds are drawn, and my office lights are off. It appears to be a "solar" calculator that can function in the dark.
Lacking any kind of light source – natural or otherwise – my calculator works flawlessly. And it continues to do so after, what I believe to be, twenty-five years.
The most magical part of all?
The thing never breaks.
Judging by a quarter of century of impeccable service, my calculator is projected to last
I love perfection. I strive for it every day in this blog, and consistently fall short. Now here's this thing I own that is inherently…perfect. It lasts forever, and works as reliably today as it did when I bought it. It always calculates correctly – just for fun, I have double-checked its computations, comparing its results with my own pen and paper calculations, and after all these years, it has never once been wrong.
Wouldn't it be terrible if you "bad lucked" into an "Evil Calculator" that deliberately gave you faulty calculations?
ME: I have five hundred dollars in the bank.
EVIL CALCULATOR: Heh, heh, heh.
My calculator neither gloats nor misleads. It is one hundred per cent decent and correct. Every single time. Since, somewhere around, 1986. I did that in my head – 2011 minus 25 – but I could have done it on my calculator. And I'm certain the answer would be exactly the same.
What's interesting to me is, I look around my house, and do not see a single piece of equipment that, like my calculator, has the "Expiration Date" of "Never!" This magnificent gizmo seems to be one of a kind. And you can easily understand why.
The customer may be ecstatic about such a product. The free enterprise system? Considerably less so.
"Would you like to buy a solar calculator?"
"I already have one. And it's projected to last forever."
Uh-oh. Say goodbye to the Capitalist System. Open the window, and you'll hear the house of cards called "business" come crashing to the ground.
If I were Swedish and voting, I would readily accord the person who invented the calculator that lasts forever the "Nobel Prize for Mechanistic Immortality." Judging from the dearth of devices boasting similar longevity, what seems clearly to have happened is that, instead of being feted, huzzahed and carried around on shoulders, the inventor of this devise was instead vigorously shaken, bopped over the head repeatedly with a mallet, had his head submerged in water for several minutes, after which, he was forced down a gauntlet of club-wielding company shareholders and assembly line workers, to the point where the battered genius who invented the reasonably priced product that lasted forever agreed to promise, through swollen lips and shattered teeth, that
He would never ever do it again.


text:
It's incredibly difficult to assemble a "Best Of" list in comics given the massive variety of publications that arrive in a single calendar year. That's especially true in 2017 when many of the largest direct market publishers offered some incredible shake ups to ongoing lines as well as some explosive debuts. In order to make sure as many great titles got an opportunity to shine as possible, this list is here to highlight the best indie comics of 2017.
Poppies of Iraq makes a tumultuous and complex modern history and culture vastly more approachable through the use of perspective. Findakly's life is combined with Trondheim's cartoooning in order to provide glimpses of life in Iraq prior to the United States' invasion. The comic moves between an autobiographical narrative and small memories of customs, life outside of the country today, and family photos. The result is an immersive experience that makes distant experiences seem both present and personal.
Sticks Angelica, Folk Hero is yet another illustration that there is no modern cartoonist as prolific, innovative, or surprising as Michael DeForge. The tale of Sticks is an intricately woven set of stories that include DeForge himself as an attempted biographer and many bizarre animals, some of which happen to share names with DeForge's own colleagues. Through this lens the comic examines how we build narratives, both for ourselves and others, in a world that is unlike anything else on the comics page, but comes to resemble our own in the most curious of ways.
Boundless presents Jillian Tamaki as one of the greatest living comics creators of our era in a collection of short stories that often attain the level of transcendence. They range in style from the mundane to the fantastical, but are bound by a similar sincere and explorative tone that becomes transfixing when read together. Tamaki provides a spellbinding set of comics that encourages us to consider our relationships with society, one another, and ourselves through a diverse set of perspectives and settings.


text:
SAN JOSE — Three homicides in about a four-hour period Sunday added up to a bad day in the city, but it was made worse when San Jose police confirmed Monday that the first two fatalities were boys believed to be between the ages of 15 and 17.
"Obviously, this is not the way you want to start the summer," said police spokesman Sgt. Jason Dwyer. "The reality is that you're going to have anomalies like this. Our concern is if it becomes a pattern. But, obviously, these are terrible incidents, particularly the one involving minors."
The two boys were shot near McKee Plaza in East San Jose, near Rinehart Drive.
"I was at McDonald's, and I heard two gunshots," said Anjelica Herrera, 38, on Monday. "When I came out, the two boys were on the ground."
Police responded to a 911 call about the two teenagers just before 6:30 p.m. Later in the evening, a third man was shot to death in South San Jose.
The fatalities brought the city's homicide total this year to 19.
"One homicide is too many," Mayor Chuck Reed said Monday after a Memorial Day ceremony at Oak Hill Memorial Park. "We're up to 19 now, and that's far too many. But people should know that our police department does a great job investigating, catching the bad guys and putting them in a jail. They're putting in a lot of overtime to make sure that happens."
The homicides put the city roughly on pace to match last year's total of 46, which was a 20-year high. If San Jose were to reach 40 homicides again, it would mark the first time since 1991-93 that the city tallied at least 40 in three consecutive years.
Of the previous 16 homicides, two were gang-related.
Authorities were tight-lipped Monday, citing the on-going investigations. The Santa Clara County Medical Examiner's Office still was confirming identities and locating next of kin. No suspects have been identified, and Dwyer said it was unclear if either incident was gang-related.
"We know that in both of these cases, somebody out there knows what happened," Dwyer said. "The two teenagers could be anybody's kids. The other man who was shot has relatives. We're trying to appeal to somebody's morals and ethics to do the right thing and give us the information we need."
By late Monday afternoon, a crowd of at least 20 grieving teenagers had gathered at the scene of the homicides on Rinehart Drive, located in a neatly kept, working-class neighborhood. A large photo of one of the victims was taped to a tree above a shrine of flowers and candles.
Although several teens posed for smartphone pictures of themselves at the shrine, none would clearly identify the two victims or where they attended school.
Early Sunday night, officers responded to a 911 call reporting two people shot on Rinehart at Clogston Court, not far from a large shopping center on McKee Road. Patrol officers found the two victims on the sidewalk in front of a row of townhouses, both apparently shot with a handgun.
One died at the scene. The other was taken to a hospital, where he was pronounced dead. Sunday, a police spokesman could describe one suspect only as a "Hispanic male, younger, on a BMX bicycle."
At 10:11 p.m., police responded to another 911 call in the 100 block of Hayes Avenue, near Oak Grove High School, in South San Jose, where a man had suffered at least one gunshot wound. He was pronounced dead at the scene about 15 minutes later.
Early Monday morning, that neighborhood was quiet. The only sign that a shooting had occurred was torn police crime tape that appeared to have been blocking a section of the sidewalk along Hayes in front of the Orchard Park Apartments.
As police investigated the homicides, they also were involved in a manhunt after a report at 12:14 a.m. Monday of a man brandishing a gun in a parking lot in the 300 block of North Jackson Avenue.
A patrol officer spotted the suspect's vehicle and followed for several blocks before losing it. A short time later, it was found crashed and unoccupied on Commodore Drive, but police were unable to locate the man after an extensive search of the neighborhood.
At 6 a.m., police received a call from an employee of a business in the 900 block of Lundy Avenue about a suspicious male. Responding police determined he was the suspect and arrested him in possession of a handgun. The man was admitted to a hospital for injuries presumably sustained when he crashed the car, which was stolen.
"This was not the kind of day where you wanted a guy running around in a stolen car, with a gun and who had an outstanding warrant," Dwyer said. "It was a great arrest."
Anyone with information about the shootings is asked to call the San Jose Police homicide department at 408-277-5283.
Staff writer Robert Salonga contributed to this report.
Contact Mark Emmons at firstname.lastname@example.com and Dana Hull at firstname.lastname@example.com.


text:
Rod Lighting
A selection of battery or chemical lights to help you see bites in the dark.
Shore Fishing Tackle Accessories - Rod Lighting
We have lots more products in store than currently displayed here. If you can't see what you are looking for, please contact us for advice. We can also take your order over the phone (01323) 460441.


text:
Óż░ÓźćÓż©Óż¼ÓźłÓżĢÓźŹÓżĖÓźĆ Óż▓ÓźćÓż¼ÓźŗÓż░ÓźćÓż¤Óż░ÓźĆÓż£
Óż¼ÓźĆÓżÅÓżĖÓżł: 500359 | NSE: RANBAXY | ISIN: INE015A01028 | Pharmaceuticals
- Óż¬ÓźŹÓż░Óż¼ÓżéÓż¦Óż©
- Óż¬Óż┐ÓżøÓż▓Óźć ÓżĄÓż┐ÓżĄÓż░ÓżŻ
- Óż¬ÓźāÓżĘÓźŹÓżĀÓżŁÓźéÓż«Óż┐
- Óż▓Óż┐ÓżĖÓźŹÓż¤Óż┐ÓżéÓżŚ
- ÓżĖÓźŹÓżźÓżŠÓż©
- Óż¼ÓźŗÓż░ÓźŹÓżĪ Óż¼ÓźłÓżĀÓżĢ
- ÓżĄÓżŠÓż░ÓźŹÓżĘÓż┐ÓżĢ ÓżåÓż« Óż¼Óźł'┐Į ÓżĢ/ ÓżłÓż£ÓźĆÓżÅÓż«
- Óż▓ÓżŠÓżŁÓżŠÓżéÓżČ
- Óż¼ÓźŗÓż©ÓżĖ
- Óż░ÓżŠÓżćÓż¤ÓźŹÓżĖ
- ÓżĄÓż┐ÓżŁÓżŠÓż£Óż©
|ÓżĢÓżéÓż¬Óż©ÓźĆ ÓżćÓżżÓż┐Óż╣ÓżŠÓżĖ - Óż░ÓźćÓż©Óż¼ÓźłÓżĢÓźŹÓżĖÓźĆ Óż▓ÓźćÓż¼ÓźŗÓż░ÓźćÓż¤Óż░ÓźĆÓż£
1961 - The Company was Incorporated on 16th June, 1961 at Delhi. The Company Manufacture drugs, medicines, cosmetics and chemical products. The company also markets a wide range of products including a number of life saving antibiotics. 1973 - The shareholders of the Company offered for sale to the public during October simultaneously with the public issue of shares 63,535 equity shares of Rs 10 each of the Company at par. 1977 - The Company had set up a joint venture company with local participation in Nigeria. The equipments to be supplied against the Companmy's contribution to the equity capital were ordered. These were shipped during 1978 and were received and installed in Nigeria. Production commenced in early 1980. 1984 - Ranbaxy Investments Ltd., Medicare Investments Ltd., and Cheminvest Ltd., became subsidiaries of the Company. 1985 - Approval of the Malaysian Government was received for a joint venture project. The project commenced production in July 1987. - In October the Company made a rights issue of 1,00,000 equity shares of Rs 10 each linked to 15,00,000-15% secured redeemable non-convertible debentures of Rs 100 each, both at par on the following basis: - (i) 9,09,000 equity shares tied to 13,63,500-15% debentures to the existing equity shareholders and holders of the convertible parts of 13.5% secured debentures in the ratio 27 debentures and 18 equity shares for every 50 equity shares or 10 convertible parts of the 13.5% debentures held, - (ii) 71,000 equity shares tied to 1,06,500 debentures as preferential allotment to equitable basis to employees, and - (iii) 20,000 equity shares tied to 30,000 debentures to business associates. The issue was oversubscribed and the Company allotted a further 2,50,000 equity shares tied to 3,75,000 bedentures to retain oversubscription. - Ranbaxy Drugs Ltd., became a subsidiary of the Company. Montari Agro Chem Investment Ltd., Montari Chemicare Investments Ltd., Chahel Investment & Trading Co., Ranpharm Investment Ltd., Raicure Investment Ltd., & Vidyut Inv. are subsidiaries of the Company. 1986 - 9.8% Pref. shares redeemed. 39,510 equity shares issued in conversion of 13.5% debentures. 1987 - An antibiotic plant at Toansa, Dist. Hoshiarpur (Punjab) and the Nalidixic Acid plant as SAS Nagar (Punjab) were commissioned. - 7,000-11% Pref. shares redeemed. 45,680 equity shares issued in conversion of 13.5% debentures. (Final conversion). 1988 - A new broad spectrum oral fluoroquinolone of loxacin under the brand name Zanocin was launched in the market in April 1990. - The Company offered 16,64,775-12.5% secured fully convertible debentures of Rs 100 each for cash at par aggregating to Rs 16,64,77,500. Of these, 15,85,500 debentures were offered to the shareholders on rights basis in the proportion 30 debentures: 100 equity shares (all were taken up). The balance 79,275 debentures were offered to the employees (including Indian working Directors) (all were taken up). Additional 2,49,716 debentures were allotted to retain oversubscription (2,37,825 debentures to the shareholders and 11,891 debentures to the employees). - Each debenture was converted into 2 equity shares of Rs 10 each at a premium of Rs 40 per share on 31.3.1989. Accordingly, 38,28,982 equity shares of Rs 10 each were issued. Subject to necessary approvals being obtained, the Company proposed to issue 13,67,097-12.5% secured redeemable partly convertible debentures of Rs 300 each on rights basis to the existing equity shareholders in the ratio of 9 debentures for every 100 equity shares held. Simultaneously, the Company proposed to offer, 68,355 debentures to the employees/workers of the Company. - As per the proposed terms of issue, part-A of Rs 200 of each debenture will be converted into four equity shares of Rs 10 each at a premium of Rs 40 per share at the end of 6 months from the date of allotment. The non-convertible part-B of each debenture will be redeemed at part at the end of 7th year from the date of allotment. 1990 - A new plant was set up at Sahibzada Ajit Singh Nagar for the production was commissioned. A bulk facility to produce newer fluoroquinolones was also being set up at Dewas. - On 1st June, the scheme of arrangement for spinning-off the pharmaceutical plant at Okhla, New Delhi of the Company to Pharmax Corporation Ltd. was approved by the Honourable high court of Punjab & Haryana. - Tata Hotels Ltd., is a subsidiary of the Company with a holding of 7,500 equity shares of Rs 10 each out of 7,600 equity shares issued. Since 1990, Tata Hotels Ltd. ceased to be a subsidiary of the company. 1991 - The Company proposed to undertake backward integration into fermentation based products such as Penicillin and Cephalosporin-C. These were to be implemented at Paonta Sahib in Himachal Pradesh, a new complex being developed for bulk drugs. - 2,250 Pref. shares redeemed on 3.9.91. 60,75,988 bonus equity shares issued in prop. 2:3. 1992 - The Company offered 13,67,097-12.5% partly convertible debentures of Rs 300 each on Rights basis in the proportion of 9 debentures: 100 equity shares held. All were taken up. Additional 2,05,065 debentures were allotted to retain oversubscription. - 68,355 debentures of Rs 300 each were also issued to the employees' on an equitable basis. (All were taken up). Additional 10,253 debentures were allotted to retain oversubscription. - Part A of Rs 200 of the face value of each debenture was to be compulsorily converted into 4 equity shares of Rs 10 each at a premium of Rs 40 per share at the end of six months from the date of allotment of debentures. - Part B of Rs 100 of the face value of each debenture was to be redeemed at par at the end of 7 years from the date of allotment of debentures. - RLL has three successful overseas joint ventures in Nigeria, Malaysia and Thailand. A joint venture recently incorporated in India with Eli Lilly -- a leading original research company in pharmaceuticals 1993 - During September the Company offered 24,51,719-12% fully convertible debentures of Rs 300 each on Rights basis in the proportion 15 debs: 200 equity shares held (all were taken up) (18611 debs. were kept in abeyance). - Another 1,22,586-12% debentures were offered to the employees as an equitable basis (all were taken up). - Part A of Rs 125 of each debenture was to be converted into one equity share of Rs 10 each at a premium of Rs 15 per share on the date of allotment. Accordingly 25,55,694 equity shares were allotted on 5.12.93. - Part B of Rs 175 of each debenture was to be converted into one equity share of Rs 10 each at a premium of Rs 165 per share on the expiry of 12 months from the date of allotment. Accordingly 25,55,694 equity shares were allotted on 6.12.1994. - The Company also offered 40,86,197-15% Non-Convertible debentures with warrants attached to it on Rights basis in the proportion 25 NCDS with warrants 8,200 equity shares held (all were taken up). - Another 2,04,310-15% NCDS were also offered to the employees on an equitable basis (all were taken up). These would be redeemed in three instalments of Rs 66, Rs 67 and Rs 67 each at the end of 6th, 7th & 8th year respectively from the date of allotment debentures. - Each NCP carries a warrant entitling the holder to apply for one equity share of Rs 10 each at a premium of Rs 115 per share at one or more instalment as may be decided by the Board during the period between 36th months and 60th months from the date of allotment of NCDS at half yearly intervals. - The Company also offered 85,000-12% Full Convertible debentures with warrants of Rs 300 each for cash at par to Specified Entities of the Management Group. Part A of debenture would be converted into one equity share of Rs 10 each at a premium of Rs 115 per share on the date of allotment. Part B of Rs 175 of each debenture was to be converted into one equity share of Rs 10 at a premium of Rs 165 per share. On December 6th 1994, 26,40,694 equity shares of Rs 10 ech were allotted as per the terms of fully convertible debentures issued in December 1993, Part B of Rs 175 each. - Each debenture has a warrant attached to the entitling the holder to apply for 25 equity shares of Rs 10 each for cash at a premium of Rs 165 per share in one or more instalment as decided by the Board, during the period between expiry of 12th month and 60th months from the date of allotment of debentures. - On 5th December, 32,81,154 equity shares were issued to shareholders of erstwhile Crosslands Research Laboratories Ltd. on its amalgamation with the Company. - It went public in Oct.'93 to part-finance manufacturing facilities of bulk fluoroquinolones at Dewas, MP; and dosage forms at Paonta Sahib, Himachal Pradesh. For easier access to the European markets 1994 - The Expansion and Modernisation plant for manufacture of Ranitidine and Amoxycillin and a pilot plant for R&D at Toansa were commissioned. A new plant for manufacture of pharmaceutical dosage forms at Paonta Sahib was completed. - The company allotted one hundred thousand warrants without any face value to entities of the management group on 28th July. Each of such warrants entitles the holder to subscribe to fifty equity shares of Rs 10 each at a premium of Rs 390 per share within a period of 18 months from the date of allotment. - The Company offered 51,61,290 GDSs representing 51,61,290 equity share of Rs 10 each at a price of US .375 equivalent to 604.89 (at the rate of US .00 = 31.22) per GDS on 29th June. 1995 - A Global Alliance Agreement was signed with Eli Lilly and the Company, for marketing of pharmaceutical products in U.S.A. and other countries. For the purpose of Indian joint venture, a company under the name Ranbaxy Lilly company was incorporated. - A join venture in U.S.A. for marketing of products from the Indian joint venture as also select Lilly and Ranbaxy products was proposed. For the purpose, a company under the name Lilly Ranbaxy Pharmaceuticals LLC was incorporated in the state of Indiana, U.S.A. 1996 - RLL bought a drug firm in Ireland in Jan.'96. In 1996, it acquired six leading brands from Gufic. Croslands Research Laboratories, a leading manufacturer of dermatological pharmaceutical formulations has been merged with RLL. In Oct.'98 sold off the Glat (Global Alliances and Technologies) division of Croslands to French pharma major Galderma. 1997 - The name of Ranmax Laboratories (Nigeria) Ltd., was changed to Ranbaxy (Nigeria) Ltd. - 1,50,000 equity shares of Rs 10 each (prem. Rs 630 per share) allotted on 12th June, to Ranbaxy Employees Welfare Society on exercise of rights attached with warrants allotted to the society. 2,23,958 equity shares of Rs 10 each (prem. Rs 115 per share) allotted on 1.8.1997 on exercise of right attached with warrants allotted along with NCDs of Rs 200 each on rights basis. 6,56,423 equity shares of Rs 10 each (prem. Rs 115 per share) allotted on 1st February 1998 on exercise of right attached with warrants allotted along with NCDs of Rs 200 each on rights basis - The Company has licence arrangements with M/s. Upjohn International, Kalamazoo, U.S.A., M/s. Laboratoire Choay, Paris, France and M/s. KRKA, Ljubljana, Yugoslavia for security process and technical know-how for manufacturing and marketing some of their products in India. - Croslands Research Laboratories Limited is being merged with Ranbaxy Laboratories Limited. - The company recently issued one-for-one bonus shares raising the equity capital to Rs.7.42 crore. Foreign institutional investors (FIIs) hold over 15 per cent of the company's equity. The two promoters hold around 50 per cent, the employees two per cent and the domestic institutions about three per cent. - The company already has a tie-up with the US-based Eli Lilly, which has helped it to take on the drug multinationals. - According to Gufic's managing director Jayesh Choksi, Ranbaxy Laboratories has acquired all the major pharmaceutical formulation brands of the Rs.125-crore, Mumbai-headquartered Gufic Labs. - The annual Ranbaxy research awards were presented to five scientists for their outstanding contributions in medical, pharmaceutical and clinical sciences by Sir Gustav Nossal, immunologist from Australia. - Dr Sandip Kumar Basu, Director of the National Institute of Immunology (NII), New Delhi, received the prize in the same category for his work on receptor-medicated intracellular delivery of drugs to macrophages, which are specialised cells important for the restoration of damaged cells, and for demonstrating the superior efficacy of these drugs over conventional chemotherapy. - Ranbaxy Laboratories recently pipped Nicholas Piramal to take over the Mumbai based Croslands Research Laboratories sums up his rationale for merging his 12 year old company with the Rs. 930 crore Ranbaxy Industries. - RRL has been busy establishing joint ventures, strategic alliances, acquisitions in other countries to gain access to potential global markets. RRL is one of the Indian pharma companies which was able to seize opportunities during the rigid FERA era of the seventies. - RRL has acquired Ohm Laboratories New Jersey, US and another company Rima Pharmaceuticals in the Ireland to serve the UK market and European Community. - RRL has resorted to a strategy of combining R&D with marketing probably to introduce drugs through reengineering route. Three 50:50 joint ventures with Eli Lilly and Company of US are planned, one to market products in US, another for R&D in India and yet another one to market Eli Lilly products in India. The objective is to create a large portfolio of Eli Lilly and Ranbaxy products. - Ranbaxy Laboratories Ltd, Dabur India Ltd and Great Eastern Shipping Company Ltd have signed agreements with NSDL to get their securities admitted for dematerialisation at NSDL. - Equity shares of Ranbaxy Laboratories Ltd are accepted for dematerialisation at NSDL as their registrar and transfer agents, Karvy Consultancy Services Ltd. have already established electronic connectivity with NSDL. - Ranbaxy Laboratories has entered into a 50:50 joint venture with Specialty Laboratories Inc, of US to set up a clinical reference laboratory in Mumbai as well as satellite laboratories in Bangalore and Delhi. - These companies - Delta Drugs Private Ltd, Delta Health Care Private Ltd, Delta Laboratories Private Ltd, Ranbaxy Managers Welfare Ltd and Ranbaxy Employees Welfare Ltd hold an 11.85 per cent stake in the company. In all, Ranbaxy has a share capital of 49.41 million shares. - The pharma major, Ranbaxy Laboratories, is all set to launch its first investigational new drug (IND) in the U.S. within the next 18 months. - Shareholders of Croslands Research Laboratories Ltd (CRL) will receive three equity shares of Ranbaxy Laboratories Ltd (RLL) for every seven shares held by them. According to company sources, the High Courts of Punjab, Haryana and Mumbai granted the necessary approvals for the scheme of amalgamation. - In 1997-98, it entered into a 50:50 joint venture with the New Jersey-based Schein Pharmaceuticals Inc, the generics arm of Bayer AG, Germany, for manufacture of Ranitidine. The company is the first to launch prescription products under its own label in the United States. RLL's chairman and managing director Parvinder Singh has been selected for Business India's businessman of the year 1998 award. 1998 - It has become India's first pharmaceutical company to launch prescription products under its own name and label in the U.S., the world's largest pharmaceutical market with an estimated 1997 sale of $ 101 billions. - The company has entered the U.S. ethical prescriptions market through Ranbaxy Pharmaceuticals Incorporated (RPI), a wholly-owned subsidiary of the Ranbaxy Laboratories Ltd. The entry has been made with Cefaclor capsules and suspensions. - Ranbaxy Laboratories promoter Parvinder Singh has sold around 20 lakh equity shares of the company at a price of Rs.650 per share. Over a dozen foreign institutional investors (FIIs) have picked up these shares in a deal struck by JM Financial and Morgan Stanley. - The board of directors of pharmaceutical giant Ranbaxy Laboratories Ltd has recommended a bonus issue of one share for every share held, subject to the approval of its shareholders. - Ranbaxy Laboratories Ltd and the All-India Organisation of Chemists and Druggists (AIOCD) have signed a memorandum of understanding for various trade-related issues, including the discount structure for decontrolled products of Croslands, a division of Ranbaxy. - The 0-bn US insurance major Cigna has revised its memorandum of understanding (MoU) with Ranbaxy Laboratories for general insurance, including health insurance, and has entered into a fresh tripartite MoU which includes Infrastructure Leasing and Financial Services (IL&FS) and Parvinder Singh, chairman, Ranbaxy, in his individual capacity. - Ranbaxy Laboratories received the National Award 1998' for indigenous development of technology. The company has bagged the award for the third consecutive year. - Ranbaxy Laboratories Ltd has been ranked among the leading companies in the 1998 edition of `Review 200: Asia's leading companies', the annual survey conducted by Far Eastern Economic Review. - On 28th Dec, 1998, the company issued bonus share in ratio of one new equity share for every one equity share held. 1999 - Pharma Majors Ranbaxy Laboratories Ltd and Glaxo Ltd announced an agreement for co-marketing of an advanced dosage form of the antibiotic cephalexin. - According to the co-marketing agreement, Ranbaxy will market the new dosage form as Sporidex AF, while Glaxo extends its phexin line with its innovated product. - Ranbaxy Laboratories Ltd and Cipla have entered into a strategic partnership to jointly market a select basket of drugs. - Ranbaxy Laboratories Ltd has signed an agreement with Glaxo for the co-marketing of an advanced dosage form of the antibiotic, Cephalexin. 2000 - The Company has filed an investigational new drug application for its new asthma molecule - Rbx-4638 with the Drugs Controller General of India (DCGI). Ranbaxy is the first company in the country to file an INDA for such a novel drug compound. - Eli Lilly Ranbaxy, a 50:50 joint venture between Ranbaxy Laboratories and the US-based Eli Lilly & Co., has introduced HumaPen, a new ergonimically designed, resusable insulin delivery service. - Ranbaxy Laboratories Ltd (RLL) has entered into an agreement with Knoll Pharmaceuticals Ltd (KPL) to market the latter's leading brands in select overseas markets. - The Company is launching a major supply and sale offensive in the European markets. - The Company is the eleventh largest company in the international generics market. - The Company has proposed a stock option scheme for its employees and working directors. - Ranbaxy Pharmaceutical Inc, the US arm of pharmaceutical major Ranbaxy Labs, has entered into a co-marketing alliance with Purepac to market its generic cardiac drug Enalapril Maleate in the US markets. - Ranbaxy Laboratories Ltd. has launched its generic Enalapril Maleate tablets in the US, through its wholly-owned subsidiary-Ranbaxy Pharmaceuticals Inc. - Ranbaxy's late Chairman and Managing Director Parvinder Singh's eldest son Malvinder Mohan Singh is being moved up the ladder in the company as a director. - Ranbaxy Laboratories and Cipla have expanded an existing partnership by adding one more new drug in their co-marketing arrangement. - Drug major Ranbaxy Laboratories is setting up a drug discovery laboratory in the US. - The Company has entered into a marketing alliance with Ajanta Pharma to market some of its natural products in south-each Asia. - The Company has started a bioinformatics facility on its research and development premises at Gurgaon. - The Company is set to launch a specialised Website before the actual launch of the Indian version of the wonder drug, Viagra. - Ranbaxy Laboratories has launched a website www.caverta.com with details of its sildenafil citrate brand. - Crisil has reaffirmed the P1+ rating assigned to the Rs 130-crore CP programme of the company and the FAAA rating assigned to its fixed deposit programme. - Ranbaxy Laboratories has been awarded the US Foods and Drugs Administration approval for four key anti-infective products, representing nine formulations. - Ranbaxy Laboratories is setting up a greenfield manufacturing facility in Vietnam with an investment o fover million to be spent over the next five years. - In Mar.'2000 it launched CLAFRINAST, this novel drug compound belongs to the VLA (Very Large Antigen)4 class of drug which represents a totally new mechanism for treatment of asthma. No such drug has been launched in the international market. 2001 - Ranbaxy Laboratories is set to reap a windfall after existing the joint venture with the billion US pharma major, Eli Lilly by selling its 50 per cent stake made at an equity investment of Rs 7.2 crore for more than ten times at Rs 78 crore. -July 3: The US-based Eli Lilly has bought the 50 per cent stake owned by Ranbaxy Laboratories in the joint venture Eli Lilly Ranbaxy for million. - Ranbaxy Laboratories, on August 17th, received the government's approval to begin selling Cifran-OD, a once-a-day form of the antibiotic ciprofloxacin. -Ranbaxy Laboratories and Cipla, two of the country's leading pharma firms, on August 27 announced an alliance to co-market the former's once-a-day formulation of ciprofloxacin. - The US-based Eli Lilly has bought the 50 per cent stake owned by Ranbaxy Laboratories in the joint venture Eli Lilly Ranbaxy for million. - Ranbaxy has appointed Mr Rashmi Barbhaiya as the head of research and development (R&D) at Ranbaxy. 2002 - Ranbaxy subsidiary receives tentative approval for commercialization of Lisinopril Hydrochlorothiazine Tablets - Ranbaxy Laboratories's US subsidiary has received temporary approval for an anti-hypertension drug, Prinizide, issued by US Food and Drug Administration. - Ranbaxy terminates manufacturing agreement with Eli Lilly - Ranbaxy Laboratories has recieved approval for launching the anti-asthma compound - Montelukast in India. - Ranbaxy obtains FDA approval to launch Ceftin - Ranbaxy obtains exclusive marketing rights for Nifedipine-XL from Penwest, USA - Ranbaxy Laboratories and Wockhardt on March 7th announced a strategic business alliance for the US, the world's largest market for pharmaceutical products. - Ranbaxy introduces OTC, herbal remedies - Ranbaxy's US subsidiary gets USFDA permission for midazolam syrup - Ranbaxy's subsidiary gets USFDA approval for acetaminophen - Ranbaxy enters biotechnology arena -Amarinder Singh resigns from Directorship of Ranbaxy Laboratories. - Ranbaxy & Schwarz Pharma sign a deal to develop new drug to treat benign Prostate Hyperplasia - The Ranbaxy Laboratories has got the final approval to manufacture and market cefpodoxime proxetil for oral suspension from the US Food and Drug Administration (USFDA) - Ranbaxy obtains USFDA approval for Adderall - 4 Ranbaxy drugs included in WHO list - Ranbaxy Laboratories Ltd and Procter & Gamble Pharmaceuticals - Germany GmbH (P&G) today (June 26, 2002) announced the execution of an agreement by which Ranbaxy acquires the Brand, Veratide® in Germany from P&G. - Ranbaxy Lab got regulatory approval for its clinical Phase-I trials of its potentially anti-asthmatic entity - Ranbaxy makes a breakthrough in its R&D programme - Ranbaxy garners 90% market share of cefuroxime axetil in the US market - Ranbaxy gets FDA approval for Isotretinoin - Ranbaxy gets promotion and marketing rights for Verorab - FDA approved Ranbaxy Lab's new formulation - Ranbaxy changes its Asia-Pacific base to Singapore - Ranbaxy enters into marketing pact with Aventis for Hepatitis vaccine - Ranbaxy Labs forays domestic OTC segment - Ranbaxy gets US FDA approval for hypertension drug - Ranbaxy Lab announces the launch of Ranbaxy Global Consumer Healthcare - Ranbaxy Lab members approve issue of bonus shares - Ranbaxy files highest number of PCT applications to Wipo - Ranbaxy gets US FDA permission for Lisinopril - Ranbaxy Lab got approval by WHO for its anti-AIDs drugs -T R Mulchandani retires from Directorship of Ranbaxy. -Ranbaxy Laboratories Ltd, and Synaptic Pharmaceutical Corporation USA today (July 12, 2002) announced the granting of a non exclusive license by Synaptic to Ranbaxy. In exchange for the non-exclusive license; Ranbaxy will provide an up-front licensing fee, milestone payments and royalties to Synaptic if any drugs subject to the license are developed and commercialized. - Ranbaxy Laboratories Ltd has acquired a liquid manufacturing facility from New York based Signature Pharmaceuticals Inc., on an asset purchase basis through its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc., USA. -Ranbaxy Laboratories Ltd has informed that Dr J M Khanna, President-R&D and Wholetime Director of the Company has retired on July 31, 2002. - SRL Ranbaxy, a wholly-owned venture of promoters of Ranbaxy Laboratories has received the prestigeous accreditation from the College of American Pathologists (CAP). - Ranbaxy receives approval from FDA to market Terazosin Hydrochloride - Ranbaxy gets US approval to manufacture and market terazosin - Ranbaxy enters into pact with Korean, Chinese biotech firms - The project of Ranbaxy Laboratories 'Crusoe,' initiated by Ranbaxy earlier this year, is well on track to result in a saving of Rs 100 crore by the year '03 by way of operational efficiencies in various functional areas. - Ranbaxy Labs gets US approval for Augmentin Version - Ranbaxy Laboratories Ltd. (RLL) and Nippon Chemiphar Co. Ltd (NC) and Nihon Pharmaceutical Industry Co. Ltd. (NPI)(a subsidiary of NC) based in Tokyo, Japan announced a business alliance agreement for US$ 50 Bn (JPY 600 billion) pharmaceuticals market in Japan. - Ranbaxy Laboratories Ltd has informed the Exchange that Ranbaxy SA (Pty) a wholly owned subsidiary of Ranbaxy Laboratories Ltd and Tiger Brands' Healthcare division, Adcock Ingram on October 16, 2002 announced the formation of a 50:50 Joint Venture to exclusively sell and distribute Ranbaxy's range of anti-retroviral products in South Africa - Ranbaxy Laboratories Ltd has informed the Exchange that it has announced an exclusive licensing agreement with K S Biomedix Ltd (KSB), a U K based bio-pharmaceutical company for marketing TransMID TM - Ranbaxy Laboratories Ltd's fully owned subsidiary Ranbaxy Pharmaceuticals Inc, has secured the final approval from the US Food and Drug Administration (USFDA) to manufacture and market amoxicillin for oral suspension 2003 - Prof Virander S Chauhan and Dr Kanury V S Rao from the International Centre for Genetic Engineering, and Prof Samir K Brahmachari from the Institute of Genomics and Integrative Biology, all from Delhi, are the seven scientists who bagged Ranbaxy Research Awards for the year 2001. - Ranbaxy Laboratories has rolled out the GlaxoSmithkline's antibiotic called Augmentin, in the US market - Ranbaxy Launches next Generation Anti-Retroviral for the first time in India - Ranbaxy Laboratories Ltd on February 10, 2003 has announced the launch of a high end advanced Cephalosporin, Cefprozil, under the brand name Refzil O - Ranbaxy obtains USFDA approval to market Augmentin clones - Ranbaxy gets US FDA nod for Cefadroxil Oral Suspension USP - Ranbaxy receives tentative approval for manufacturing & marketing of Fluconazole Tablets - Ranbaxy enters into collaborative research with medicines for development of Anti-Malarial Drug - Ranbaxy receives USFDA approval to manufacture and Market Ofloxacin Tablets - Ranbaxy announces FDA approval for the manufacture and commercialisation of Isotretinoin Capsules - Ranbaxy Laboratories obtains approval from USFDA to manufacture Ganciclovir Capsules - Ranbaxy receives USFDA approval for AIDS drug - Ranbaxy Lab gets nod from FDA USA for Mfg, marketing fluconazole - Ranbaxy Latoratories is at the verge of becoming a Zero-Debt company. The company's secured and unsecured debt is curtailed to less than Rs 7 crore, this will ultimately result in substantial savings in the interest outgo. - Ranbaxy Laboratories has obtained US Food and Drug Administration (FDA) approval to unveil a new amoxicillin antibiotic drug in US market. - Ranbaxy receives USFDA approval to manufacture & market Loratadine 10 Mg tablets in the OTC market - Ranbaxy Labs and Kasturba Medical College owned by the Manipal Group have jointly started a clinical research centre in Manipal. - Ranbaxy receives USFDA approval to manufacture & commercialize Ofloxacin tablets - Ranbaxy launches High end anti infective injectable for the first time in India - Ranbaxy gains USFDA approval for commercialization of Riomet - Ranbaxy Laboratories has inked an agreement with the Andhra Pradesh Government for starting a research centre in the State. - Ranbaxy gets FDA approval for diabetes drug - Company's Animal Health Division signs marketing agreement with Alltech Biotechnology for YeaSacc 1026 Bolus, a highly valued product in the dairy cattle segment - Ranbaxy Laboratories Ltd and GlaxoSmithkline plc (GSK) have entered into a drug discovery and clinical development collaboration covering a wider range of therapeutic areas. -United States Food and Drug Administration has permitted Ranbaxy Laboratories Ltd to manufacture and commercialise Metformin HCI oral solution 100 milligram per millilitre. -The company has received prestigious National Safety Awards for the year 2001 & 2002 -Unleashed a cholesterol-reducing agent called 'Rosuvas (rosuvastatin)', which reduces triglycerides and raises HDL.. -Ranbaxy gets FDA approval to market cephalexin -Got approval from US FDA for the manufacture and marketing of Merck & Co Inc's cholesterol-lowering drug generic Zocor. -Company has received tentative approval from the office of Generic Drug of the US Food & Drug Administration to manufacture and market Metformin Hydrochloride extended-release tablets, 500 MG. -Secured USFDA approval for Simvastatin drug -Ranbaxy gets approval from US FDA for selling its generic form of Bristol-Myers Squibb's cholesterol-reducing Pravachol. -Received tentative approval from the office of generic drugs of the US Food and Drug Administration to manufacture and market pravastatin sodium tablets 10mg, 20mg, 40mg, and 80 mg. -Ranbaxy Laboratories granted first USFDA Approval to manufacture and Market Cefaclor Tablets 2004 -Ranbaxy Laboratories Ltd announced that all the necessary formalities and consents required for the conclusion of the acquisition transaction of RPG (Aventis) SA have been obtained and that the acquisition is now complete. With this, RPG (Aventis) SA France has now become a wholly owned subsidiary of Ranbaxy. -Ranbaxy receives USFDA approval to commercialise Minocycline Hydrochloride Tablets USP -Ranbaxy Laboratories Ltd has informed that the Stock Exchange, Ahmedabad has advised delisting the securities of the Company effective January 15, 2004. - In an attempt to tap the domestic billion herbal medicines market, Ranbaxy Laboratories Ltd on Jan 21 unveiled three new brands under the `New Age Herbals' brand. As part of its expansion in the over-the-counter (OTC) segment, the company has launched Olesan Oil for cold, Olesan cough syrup and Eat Ease, an appetite enhancer. Ranbaxy had forayed into the OTC market through a separate division - Ranbaxy Global Consumer Healthcare (RGCH) in October 2002 and is hoping to launch five to six products this year. -Ranbaxy Laboratories Ltd at its meeting held on January 23, 2004, has approved the appointment of Mr Gurcharan Das as an Additional Director on the board of directors of the company. -Ranbaxy Laboratories Ltd has signed a research agreement with the Institute of Nuclear Medical and Allied Sciences (INMAS) for screening and evaluation of formulations and New Drug Delivery Systems (NDDS) using Gamma Scintigraphy. -Ranbaxy unleashes liquid form of diabetes drug in US market -Introduces its first branded prescription medicine, Visclair tablets 100 mcg (Mecysteine HCL) in the UK -Surpasses global sales of billion (February 2004, MAT Basis) -Launches Forzest (Tadalafil), its most recently approved prescription medicine for the treatment of erectile dysfunction (ED) in men -Bags tentative USFDA approval to manufacture and market Quinapril Hydrochloride tablets used for the treatment of hypertension -Delists shares from Ludhiana Stock Exchange -The outgoing CEO and MD of Ranbaxy, Mr D S Brar, has joined the board of Jerry Rao-promoted Mphasis as an independent director -Ranbaxy receives Tentative approval to market Fenofibrate tablets - Ranbaxy Laboratories sets up two more wholly-owned subsidiaries in US taking total number of US subsidiaries to eight from six last year. -Drug company Ranbaxy Laboratories Ltd said on June 22 that its anti-diabetic drug has got the final approval from regulatory authorities in the US -Ranbaxy & Atrix sign a licensing Agreement for Prostrate Cancer Drug in India -DS Brar exits from Ranbaxy Laboratories Ltd -Ranbaxy's anti-cancer drug Metformin is learnt to have received the final approval from the US Food and Drug Administration (FDA) -Indian pharma major Ranbaxy Laboratories has received final approval from the US FDA to manufacture and market Fluconazole tablets and oral suspension in varying dosages in the US. -Ranbaxy ties up with Axis-Shield to cure Rheumatoid arthritis - Ranbaxy Laboratories Ltd receives approval from U. S. Food and Drug Administration to manufacture and market Loratadine Syrup (Loratadine Oral Solution, USP), 5mg/5ml that is available to patients as an OTC product. - Receives tentative approval from the US Food and Drug Administration for generic anti-depressant, Gabapentin, in capsule form -Signs collaborative research agreement in the area of New Drug Discovery research with Avestha Gengraine Technologies Pvt Ltd (Avesthagen) -Ranbaxy prolongs partnership with Aventis -Ranbaxy inks pact with Ventiv to market Sotret in US -Ranbaxy launches Flotral for urological disorder amongst ageing males -Ranbaxy announces launch of Quinapril Tablets by Teva 2005 - Receivs approval from the U.S. Food and Drug Administration to manufacture and market Clarithromycin XL 1000 mg tablets. -Ranbaxy in alliance with Novavax to step in to biotech sector -Ranbaxy Laboratories Ltd enters into collaborative agreement with National Chemical Laboratories, Pune and Department of Science & Technology in the area of New Drug Discovery. - On May 24, 2005 launches its approved generic formulation of Clarithromycin immediate release (IR) tablets, 250 mg and 500 mg, in the US markets. -Ranbaxy's Joint Venture with Nippon Chemiphar Ltd launches Vogseal 0.2mg & 0.3mg tablets for Diabetes -Ranbaxy sets up additional manufacturing facility in Malaysia -Ranbaxy opens third state of the art R&D facility on Gurgaon campus -Company has splits its Face value of Shares from Rs 10 to Rs 5 2006 -Ranbaxy Laboratories enters into a strategic alliance with Zenotech -Ranbaxy ties up with Ipca to tap US market -Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for NCE Drug in the Gastroenterology Segment -Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for NCE Drug in the Gastroenterology Segment. -Ranbaxy Appoints Atul Sobti as COO. -Ranbaxy Laboratories Ltd has announced that the Company has entered into a collaborative agreement with the Department of Science & Technology (DST), Government of India, New Delhi, in the area of New Drug Discovery Research (NDDR). -Ranbaxy granted final USFDA approval to Market Simvastatin 5, 10, 20 & 40 MG Tablets. 2007 -Ranbaxy Laboratories Ltd and GlaxosmithKline (GSK) on February 06, 2007 have signed a new multiyear R&D agreement that modifies and expands the terms of their strategic alliance established in 2003 to provide the Company expanded drug-development responsibilities and further financial opportunities. - Ranbaxy unveils asthma inhalation capsules. - Ranbaxy Laboratories Ltd has received final approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base). - Ranbaxy Laboratories Ltd on August 22, 2007 has the launch of Roliflo OD (combination of Tamsulosin and Tolterodine) brand in the Indian market for the management of bladder outlet obstruction with concomitant overactive bladder, a chronic urological disorder. This is a Novel Drug Delivery System (NDDS) product which is being introduced for the first time in India. 2008 -Ranbaxy Laboratories on July 28 said it has launched the generic version of Omeprazole capsules, used in the treatment of acid related diseases in the US healthcare system. 2009 - Canada approves Ranbaxy's anti-hypertension drug - Daiichi launched Ranbaxy drugs in Japan -Ranbaxy subsidiary makes a deal with German health insurer - Ranbaxy launched Daiichi Sankyo's innovative antihypertensive drugs 2010 - Ranbaxy Laboratories Limited (Ranbaxy) has launched a New Chemical Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology market. This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan (SPI) allowing Ranbaxy, exclusive marketing rights, for India, 7'he introduction of this NCE, significantly strengthens Ranbaxy's presence in the Dermatological segment, - Ranbaxy Laboratories has entered into an agreement with US-based Pfenex Inc for developing biosimilars. Biosimilars are drugs which are manufactured with the use of biotechnology. - Ranbaxy has launched a generic version of antiplatelet agent Prasugrel, Prasita, in India says a report by Daiichi Sankyo and Ranbaxy Laboratories. - Ranbaxy arm bags Rs 605 cr order in South Africa - Ranbaxy Laboratories Limited (Ranbaxy) signed the Agreements with Biovcl Lifesciences Private Limited (Biovel), Bangalore, India, providing for the acquisition of product rights and a manufacturing facility, from Biovcl. - Ranbaxy and Pfenex Announce Collaboration for the Development of a Biosimilar Therapeutic Protein. - Ranbaxy Lab - Ranbaxy Launches Antiplatelet Agent Prasugrel in India -Registered Office of the Company has been shifted To A-41, Industrial Area Phase VIII-A, Sahibzada Ajit Singh Nagar, Mohali - 160 071 (Punjab) 2011 - Ranbaxy Laboratories has entered into an in-licensing agreement with Gilead Sciences, Inc. for three new HIV/AIDS drugs which are currently in late-stage clinical development. - Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative Encompassing India, Cameroon and Tanzania - Ranbaxy and The Government of Yaroslavl Region, Russia, sign MOU for cooperation in the field of Healthcare and Medical Science. - Ranbaxy Announces Launch of Atorvastatin, Generic Lipitor«, the US - Ranbaxy enters into a licensing agreement with Gilead Sciences to manufacture and market three anti-HIV drugs in India and developing countries. - Ranbaxy honored with NJBIA award for excellence in New Jersey Business Expansion 2012 - Ranbaxy Launched Absoricatm (Isotretinoin) Capsules In The U.S. Healthcare Market - Ranbaxy Delivered Strong Overall Business Performance; Improvement In Base Business Sales And Margins - Ranbaxy Launched Authorized Generic Of Evoxac In The U.S. Healthcare Market - Ranbaxy received Approval To Set Up Greenfield Manufacturing Facility In Malaysia - Ranbaxy Launched Authorized Generic Of Pioglitazone In The U.S. - Ranbaxy Entered Into An In-Licensing Agreement With Gilead Sciences To Promote Access To Reduced Cost Generic Emtricitabine And Emtricitabine-Containing Fixed-Dose Antiretrovirals In Developing Countries - Daiichi Sankyo And Ranbaxy Launched Hybrid Business In Venezuela 2013 - Daiichi Sankyo Company, Limited (Daiichi Sankyo) and Ranbaxy Laboratories Limited (Ranbaxy) announced their intention to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model, which is expected to commence business on April 1, 2013. 2014 -CCI approves Ranbaxy acquisition by Sun Pharma
|ÓżĖÓźŹÓż░ÓźŗÓżż: Óż░ÓźćÓż▓ÓźĆÓżŚÓż░Óźć Óż¤ÓźćÓżÜÓż©ÓźŗÓżĄÓżŠ


text:
Member since: 2013
Organization: Sygnature Discovery Ltd
"The machine is easy to use and the software is very friendly to use as well. The service persons are very friendly and helpful."
Member since: 2013
Organization: SK Telecom
Application Area:automation for research and development
"It is a quite impressive idea to support automation in a small bench top instrument. It is useful for the beginning stages of research. If you have a small experimental desk space this equipment is a good candidate. However, you should consider other instruments if you want to do lots of sample jobs. It can fit in even the tightest of spaces, with an enviable 650x450 mm footprint. It can be used in several kinds of application areas in bio and healthcare area."
Member since: 2013
Organization: GlaxoSmithKline
Application Area:Reagent addition, tranfer and compound transfer
"This is a reliable contact dispenser, which can dispense accurately from 2ul or higher. This system works for 384 well plate and 1536-well plate, which need transfer from 384-plate as a source plate. The percentage CV is usually about 5% or less. We routinely use it for reagent addition. For compound addition, we use it for transfer from serially diluted compound sourcing plate. The down side compared with non-contact dispenser is that the tip cost is a concern for high throughput screen. At a recent exhibition, I note that there are some new features made to this liquid handler. These include 1536-well head, which eliminates the needs for transfer for 1536-well plate stamping or transfer. Also, the plate tower for housing the plates has increased by more than 2-fold. These are unique features and I cannot wait to try it out. Based on my years of experience, I would recommend this product to a colleague and I would encourage them to get the newer versions."
Member since: 2011
Organization: CRT
"Nanolitre dispensing made easy, fits most current processes without adaptation. It allows access to low volume dispensing technologies. Great accuracy and precision."
Member since: 2009
Organization: SCHERING-PLOUGH
"I inherited an old, used Cybi-well from a colleague, and despite years of service, it still functions. As an untrained user I had difficulty with the scripting software, but their applications specialist was very helpful."
The CyBio® Well pipettor can be configured with 96 or 384 channels. The working volume range spans from 200 nL to 1000 µL depending on pipetting head.
The pipettor is ideal for HTS or research environments using disposable tips. In only 20 seconds, it pipettes and transports a 384-well microplate; in 30 seconds and in just four steps, it processes a 1536-well microplate. Procedures can be quickly and easily created with the CyBio® Composer software. The system consists either of a 3-, 4- or 5-position plate carriage respectively of a circular 10 position transport system with space for processed plates and other accessories such as tip wash station and reagent reservoirs. Optional stacker or dispenser integration together with the involvement of versatile peripheral devices can be easily implemented.
Manufacturer Analytik Jena AG | Available Worldwide4.1 / 5.0 | 10 reviews


text:
18K Rose Gold set with 3 White Diamond bars and 8 White diamond pave stars on Coral Leather.
£6,025 Sold Out
Where possible, it is best to have your Tomasz Donocik Jewellery professionally cleaned by your local jeweller.
To keep your jewellery sparkling at home we recommend using appropriate cleaning products. Keep jewellery in its original packaging or pouch to avoid tarnishing and scratching.
Rhodium plating will naturally wear off gradually over time, however perfume, chlorine and cleaning products will speed up this process and may cause tarnishing, damage and loss of stones.
For repair enquiries please contact email@example.com
Delivery & Returns
Free shipping worldwide.
Unworn jewellery is eligible to be returned or exchanged within 14 days of receipt. All custom pieces and bespoke orders are final sale.
For more information please see our full terms and conditions.


text:
France Trying to Cut Down Amazon
Today in international tech news: France plows ahead with plans to stop Amazon's dastardly discount-plus-free shipping deals. Also: Apple ditches an iPhone app designed to circumvent China's Great Firewall; Google launches a vending machine for video games in Japan; Google unveils a Street View-ish feature for historical sites in India; and HTC dips into the red.
In France, members of parliament unanimously supported a bill designed to restrict Amazon's ability to discount books.
In particular, the lawmakers want to prohibit Amazon's practice of packaging a 5 percent discount with free delivery, a deal so tantalizingly awesome that France is worried about the livelihood of independent bookstores.
The vote brought together right-wing and left-wing parliamentarians who, while not quite as acrimonious as the U.S. right and left, are nonetheless usually at odds.
"Everyone has had enough of Amazon," Aurélie Filipp, France's culture minister, said last year, and the notion was reinforced over the summer when France started publicly floating the idea of a ban on Amazon's discount-and-free shipping combo.
The head of Amazon France said that the bill would be bad for consumers, who often "live far from any bookshop and appreciate being able to buy their books online."
[Source: The Guardian]
Apple Shelves App For Chinese Firewall
Apple pulled the plug on an iPhone app that enabled users to skirt government-imposed firewalls and access would-be restricted sites in China.
The free app, "OpenDoor," surely didn't sit well with Beijing, which likes to keep a tight handle on what websites its citizens can and can't access. Apple has not been bashful about how important China is to the company's future. To that end, Apple held an event in Beijing last month to launch its new iPhones, marking the first time the company ever held tandem events in the U.S. and China.
That said, Chinese regulators hold the keys to the market, so Apple is walking a tightrope trying to appease both consumers and regulators.
[Sources: BBC and Radio Netherlands]
Google's Video Game Vending Machine
Google has unveiled a Google Play vending machine in Japan that allows people to download video games via Android devices.
Customers are supposed to take their phone and press it to a pad on the vending machine; a selected game will download automatically to the device. A large LCD screen on the machine lets customers know the download was successful.
There are both free and paid games available, although the larger purpose of the machines — other than that they're fun and quirky — isn't entirely clear.
[Source: Engadget via Gear Burn]
Google Creates Gallery of Indian Monuments
Google has created photographic tours of 100 historical monuments in India, from the Taj Mahal to underground caves.
The project, executed with the Archaeological Survey of India, isn't part of the Street View brand, but is instead an animated tour.
In 2011, the southern India city of Bangalore forced Google to abandon its Street View image collection of the city.
[Source: WatBlog via Tech In Asia]
For First Time, HTC Hits Red
Taiwanese smartphone outfit HTC lost money for the first time in the third quarter. The company posted an operating loss of about US$ 119 million, a worse performance than expected.
HTC has been contending with executive exits and, in the words of Reuters, "internal feuding." It has also faced a casing shortage for the HTC One Mini, and three of its design executives were arrested after reportedly dishing trade secrets.
HTC's share of the global smartphone market is at 2.6 percent, down from a peak of 10.3 percent in the third quarter of 2011.
[Source: Reuters]


text:
"Hungary is a stable island in the turbulent western world because the people were consulted on their opinions here, and we defended the country against illegal immigration.
"This will continue in 2017, which will be the year of revolt for European democracy.
"In many cities in Western Europe people now have no peace of mind, crimes against women rapidly multiply and the terror threat skyrockets.
"This shakes the confidence and self-esteem of the Western world. The economic slowdown, crime, terrorism, migration, indecision and insincere speech all adds up, and Western leaders won't provide the answers."
Read the entire article here.